

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



漢港控股
SINO HARBOUR HOLDINGS

SINO HARBOUR HOLDINGS GROUP LIMITED

漢港控股集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 1663)

**VOLUNTARY ANNOUNCEMENT
BUSINESS DEVELOPMENT UPDATE
SIGNING OF A STRATEGIC COOPERATION AGREEMENT**

This announcement is made by Sino Harbour Holdings Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the latest information about the Group.

The board of directors of the Company (the “**Directors**” and the “**Board**”, respectively) is pleased to announce that Zhejiang IPS Pharmaceutical Technology Co. Ltd. (“**Zhejiang IPS**”), an indirect non wholly-owned subsidiary of the Company, entered into a non-legally-binding strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Agilent Technologies China Holding Co. Ltd. (“**Agilent**”) on 30 June 2018.

Pursuant to the Strategic Cooperation Agreement, both parties shall leverage their respective experiences and resources to carry out strategic cooperation on the drug packaging materials compatibility research project (the “**Cooperation**”).

PRINCIPAL TERMS OF THE STRATEGIC COOPERATION AGREEMENT

The principal terms of the Strategic Cooperation Agreement are summarised below:

- (a) Agilent and Zhejiang IPS will conduct project cooperation in respect of the compatibility of drug packaging materials and jointly establish a technical cooperation laboratory named “Drug Packaging Materials and Drug Compatibility Experimental Project Cooperation Laboratory” (the “**Cooperative Laboratory**”). The Cooperation Laboratory will be located at the laboratory of Zhejiang IPS and be principally engaged in the development of the relevant methods for drug packaging material compatibility and related testing;
- (b) Agilent will provide the latest technical solutions and instruments at special favourable prices to assist Zhejiang IPS in introducing advanced analytical technical solutions and software management technologies and provide comprehensive technical support for the development of technologies relating to the drug packaging materials compatibility research;
- (c) Agilent will provide the latest analysis methods and general solutions to Zhejiang IPS. Specifically for the drug packaging materials compatibility research and the introduction of new technologies, Agilent will carry out more comprehensive and in-depth cooperation with Zhejiang IPS. For the popular subjects in the industry and the technical difficulties on the drug packaging materials compatibility research, Agilent will arrange for experienced technicians to assist Zhejiang IPS on tackling these difficulties and to provide support for technical application and training;
- (d) Agilent will rely on its strong local technical team and combine its past successful project experiences and the respective expertise of its team members to provide Zhejiang IPS with professional products and technical support services;

- (e) When Zhejiang IPS needs special technical application support from Agilent for any special project, Zhejiang IPS will arrange for designated person(s) to ensure the smooth progress of the cooperation project;
- (f) Zhejiang IPS will, in view of its own situations, provide the venues for training and appropriate instruments to undertake the training to be arranged by Agilent on pharmaceuticals and related fields. Agilent will be responsible for providing training courses and teaching professionals;
- (g) Subject to confidential information and the consent of Zhejiang IPS, both parties will jointly publish articles on certain popular industry solutions jointly developed and report and introduce the same at relevant meetings as and when appropriate; and
- (h) The Strategic Cooperation Agreement will expire in two years from the date of the Strategic Cooperation Agreement (the “**Team**”). Upon expiry of the Term, the Strategic Cooperation Agreement may be renegotiated and extended.

BACKGROUND OF AGILENT

Agilent is a multinational high-tech company, and its controlling shareholder is Agilent Technologies, Inc. (“**Agilent US**”), with headquarter located in Santa Clara, California, the United States. Agilent US provides life sciences, diagnostic and applied chemistry testing instruments, services, consumables, applications and expertise to laboratories around the world. Agilent US became listed on the New York Stock Exchange on 18 November 1999, with stock code of “A”.

With the strong scientific research expertise of its central laboratory, Agilent focuses on life sciences, diagnostic and applied chemistry market, and applies its professional technologies in six key areas including pharmaceutical, food, environmental and forensics, diagnostics, chemical and energy, and scientific research.

As a wholly-owned subsidiary of Agilent US in Asia, Agilent is responsible for comprehensive business, marketing and technical support of Agilent US in the Greater China region. With its headquarter in Beijing, the People's Republic of China (the "PRC"), Agilent has established three branch centres in Shanghai, Guangzhou and Chengdu, the PRC to serve businesses in different areas.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Agilent is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on the Stock Exchange) (the "Listing Rules").

REASONS FOR THE COOPERATION

The Group is principally engaged in property development business in the PRC and has entered the stem cell and drug testing service related industry since 2016.

Since the establishment of Zhejiang IPS, the Group has been sparing no effort in its top priority of making Zhejiang IPS become a leading contract research organization in the PRC, while targeting the market opportunities brought by the generic drug consistency evaluation in the PRC. In addition to enabling Zhejiang IPS to share the customer resources of Agilent, the Cooperation also focuses on the drug packaging materials compatibility research project, which is a key element in the generic drug consistency evaluation. Furthermore, Agilent, as the world's leading measurement company and researcher and manufacturer of biological science measuring instruments, will provide Zhejiang IPS with high-quality advanced instruments as well as training and support for quick technical improvement. As such, the Group believes that the Cooperation will substantially help Zhejiang IPS strengthen technical capability and improve core competitiveness.

The Board is of the view that the terms of the Strategic Cooperation Agreement are fair and reasonable and the Cooperation is in the best interests of the Company and its shareholders as a whole.

GENERAL

The Board wishes to emphasize that the Strategic Cooperation Agreement is not legally-binding and the aforesaid further business development may or may not be finalized. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

The Company will issue further announcement to inform the market of any material progress, if any, as and when appropriate or in accordance with the requirements of the Listing Rules.

By order of the Board
Sino Harbour Holdings Group Limited
SHI Feng
*Deputy Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 3 July 2018

As at the date of this announcement, the Board comprises seven Directors, including three executive Directors, namely Mr. SHI Feng (Deputy Chairman and Chief Executive Officer), Mr. WONG Lui and Ms. GAO Lan; one non-executive Director, namely Ms. CHAN Heung Ling (Chairlady); and three independent non-executive Directors, namely Mr. XIE Gang, Mr. LEE Man To and Ms. ZHANG Juan.